Inceptionr LLC Buys 7,210 Shares of Encompass Health Corporation $EHC

Inceptionr LLC grew its position in shares of Encompass Health Corporation (NYSE:EHC) by 255.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,033 shares of the company’s stock after acquiring an additional 7,210 shares during the quarter. Inceptionr LLC’s holdings in Encompass Health were worth $1,272,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in EHC. Tectonic Advisors LLC boosted its holdings in Encompass Health by 1.6% during the third quarter. Tectonic Advisors LLC now owns 5,337 shares of the company’s stock worth $678,000 after purchasing an additional 82 shares during the last quarter. Global Retirement Partners LLC increased its stake in Encompass Health by 23.0% in the 3rd quarter. Global Retirement Partners LLC now owns 449 shares of the company’s stock valued at $57,000 after buying an additional 84 shares during the last quarter. EP Wealth Advisors LLC lifted its position in shares of Encompass Health by 2.4% during the 2nd quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock worth $453,000 after buying an additional 88 shares in the last quarter. Natural Investments LLC boosted its stake in shares of Encompass Health by 1.2% in the 3rd quarter. Natural Investments LLC now owns 7,808 shares of the company’s stock worth $991,000 after buying an additional 89 shares during the last quarter. Finally, TD Private Client Wealth LLC grew its holdings in shares of Encompass Health by 1.1% in the third quarter. TD Private Client Wealth LLC now owns 8,216 shares of the company’s stock valued at $1,044,000 after acquiring an additional 91 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Down 0.7%

Shares of EHC stock opened at $106.89 on Monday. The company has a quick ratio of 1.08, a current ratio of 1.08 and a debt-to-equity ratio of 0.76. The firm has a market cap of $10.63 billion, a P/E ratio of 19.29, a PEG ratio of 2.05 and a beta of 0.71. The company has a 50 day moving average of $103.93 and a 200-day moving average of $113.58. Encompass Health Corporation has a 12-month low of $92.53 and a 12-month high of $127.99.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Thursday, February 5th. The company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.29 by $0.17. Encompass Health had a return on equity of 18.20% and a net margin of 9.54%.The business had revenue of $3.09 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the prior year, the business earned $1.17 earnings per share. Encompass Health’s revenue for the quarter was up 9.9% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. Sell-side analysts anticipate that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Wednesday, April 1st will be given a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, April 1st. Encompass Health’s dividend payout ratio is currently 13.72%.

Analyst Ratings Changes

A number of analysts recently commented on EHC shares. Wall Street Zen raised Encompass Health from a “hold” rating to a “buy” rating in a research report on Sunday, January 18th. Barclays upped their price objective on Encompass Health from $150.00 to $153.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Finally, Zacks Research lowered Encompass Health from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 19th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Encompass Health currently has a consensus rating of “Buy” and an average price target of $143.29.

Insider Buying and Selling at Encompass Health

In related news, CEO Mark J. Tarr sold 150,000 shares of Encompass Health stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $111.64, for a total value of $16,746,000.00. Following the completion of the sale, the chief executive officer owned 377,070 shares of the company’s stock, valued at approximately $42,096,094.80. This trade represents a 28.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.00% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.